-- FDA advisory panel backs Merck's blood clot-preventing drug
-- By Toni Clarke in Washington
-- Wed Jan 15, 2014 04:19PM EST
-- None



Jan 15 (Reuters) - Merck & Co Inc's <MRK.N> experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

